Market Overview

Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology

Share:

Genmab A/S (OTC: GNMSF) announced today it has entered an agreement to grant Novo Nordisk (NYSE: NVO) commercial licenses to use the DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programs. The bispecific antibodies will target a disease area outside of cancer therapeutics. Under the terms of the agreement, Genmab will receive an upfront payment of USD 2 million from Novo Nordisk.

After an initial period of exclusivity for the two target combinations, Novo Nordisk has an option to maintain exclusivity or take the licenses forward on a non-exclusive basis. Genmab is entitled to potential development, regulatory and sales milestones of up to approximately USD 250 million for each exclusive license, or approximately USD 200 million for each non-exclusive license. In addition, Genmab will be entitled to single-digit royalties on sales of any commercialized products.

"Our proprietary DuoBody technology can be used to create bispecific antibodies that target a wide variety of disease areas. Today's agreement with Novo Nordisk is an example of how we can leverage access to our unique state-of-the art antibody expertise and collaborations to generate diverse revenue streams in areas beyond cancer," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab."

This agreement is not expected to have a material impact on Genmab's 2015 financial guidance.

Posted-In: News Contracts Press Releases

 

Related Articles (NVO + GNMSF)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Jim Cramer Shares His Thoughts On GoPro, Marathon Oil And Caterpillar

Ahead Of Next Weeks FOMC Minutes & With Speculation Of A Sept. Rate Hike JP Morgan Highlights Best/Worst Currencies Vs USD 2 Yr's Before & After A Rate Hike